Financial Performance - The company's revenue for Q3 2025 was ¥74,822,074.87, a decrease of 20.18% compared to the same period last year[5] - The net profit attributable to shareholders was -¥11,212,366.34, representing a decline of 417.79% year-on-year[5] - The basic earnings per share were -¥0.1035, down 411.75% from the previous year[5] - Total operating revenue for the current period is CNY 302,688,076.14, a decrease of 8.5% from CNY 330,879,995.68 in the previous period[25] - Operating profit for the current period is CNY 28,023,489.32, a decrease of 38.9% compared to CNY 45,779,440.84 in the previous period[25] - The total profit for the current period is 31,944,668.70, a decrease from 42,917,141.46 in the previous period, representing a decline of approximately 25.0%[26] - The net profit attributable to the parent company's shareholders is 31,470,676.81, down from 39,683,076.25, reflecting a decrease of about 20.5%[26] - The basic and diluted earnings per share for the current period are both 0.2906, compared to 0.3665 in the previous period, indicating a decline of approximately 20.7%[26] - The company reported a total comprehensive income of 31,261,045.17, down from 39,555,461.09, representing a decrease of approximately 21.0%[26] Assets and Liabilities - Total assets increased by 3.44% to ¥1,605,846,303.20 compared to the end of the previous year[5] - Total assets increased to CNY 1,605,846,303.20 from CNY 1,552,474,271.14, an increase of 3.4%[22] - Total liabilities increased to CNY 234,398,997.89 from CNY 192,870,734.45, an increase of 21.5%[22] - Non-current liabilities increased to CNY 121,851,690.85 from CNY 73,085,908.60, an increase of 66.5%[22] - The company's retained earnings increased to CNY 299,866,341.34 from CNY 290,053,664.53, an increase of 3.3%[22] Cash Flow - The cash flow from operating activities for the year-to-date was ¥27,239,921.33, an increase of 14.11%[5] - Cash flow from operating activities for the current period is 27,239,921.33, an increase from 23,870,916.56 in the previous period, showing a growth of about 14.3%[28] - Cash flow from investing activities shows a net outflow of -129,634,477.79, worsening from -49,669,863.98 in the previous period[28] - Cash flow from financing activities has a net inflow of 27,968,645.03, compared to a net outflow of -31,487,820.72 in the previous period, indicating a significant turnaround[29] - The total cash and cash equivalents at the end of the period is 17,832,571.09, down from 267,304,173.29, a decrease of approximately 93.3%[29] - The company received cash from sales of goods and services amounting to 202,183,174.02, a decrease from 253,258,899.75 in the previous period, reflecting a decline of about 20.2%[28] Shareholder Information - Total number of common shareholders at the end of the reporting period is 11,085[14] - The largest shareholder, Linuo Investment Holding Group Co., Ltd., holds 34.39% of shares, totaling 37,240,000 shares, with 29,340,000 shares pledged[14] - Jinan Anfu Venture Investment Partnership holds 5.82% of shares, totaling 6,300,000 shares, with 3,380,000 shares pledged[14] - The second-largest shareholder, Wen Zehong, holds 5.00% of shares, totaling 5,414,500 shares[14] - Jinan Financial Technology Investment Co., Ltd. holds 4.72% of shares, totaling 5,110,000 shares[14] - The company has a significant concentration of ownership, with the top 10 shareholders holding a substantial portion of shares[15] - The company has a diverse shareholder base, including both state-owned and private entities[15] Investment and Acquisitions - The company plans to issue shares to acquire 99.42% equity of Shandong Hongjitang Pharmaceutical Group Co., Ltd. from 38 counterparties[18] - The company intends to raise matching funds by issuing shares to no more than 35 qualified investors[18] Other Financial Metrics - Research and development expenses rose by 58.75% to ¥35,488,296.63 for the year-to-date[11] - The company reported a significant increase in prepayments by 249.13% to ¥9,853,603.83 due to increased procurement payments[11] - The company experienced a 70.58% increase in accounts receivable, totaling ¥91,443,182.78, attributed to extended credit terms[11] - The company recorded a substantial increase in other income, which rose by 8,576.46% to ¥5,121,585.72, primarily from non-recurring government subsidies[12] - Cash and cash equivalents decreased to CNY 74,832,571.09 from CNY 178,129,204.25, a decline of 58.0%[21] - Accounts receivable increased to CNY 91,443,182.78 from CNY 53,605,977.19, an increase of 70.5%[21] - Inventory increased to CNY 151,084,601.64 from CNY 128,944,612.45, an increase of 17.2%[21] - The company has not undergone an audit for the third quarter financial report[30]
科源制药(301281) - 2025 Q3 - 季度财报